Skip to content
Screener

Agios Pharmaceuticals AGIO Q1 2026 earnings

Reported April 29, 2026 · Before market open

Revenue$20.7MBeat by $7.4M
EPS-$1.69Beat by $0.12
Revenue estimate$13.3M
EPS estimate-$1.81

Next report

Oct 29, 2026 (in a month)
Revenue estimate$53.8M
EPS estimate-$1.21

Financials

Q1 2026

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.98B+18.1%
Enterprise value$1.9B+15.2%
P/S30×-15.3×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

FAQ

When did Agios Pharmaceuticals report Q1 2026 earnings?
Agios Pharmaceuticals (AGIO) reported Q1 2026 earnings on April 29, 2026 before market open.
What were Agios Pharmaceuticals's Q1 2026 revenue and EPS?
Agios Pharmaceuticals reported revenue of $20.7M and eps of $-1.69 for Q1 2026.
Did Agios Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $13.3M by $7.4M. EPS beat the consensus estimate of $-1.81 by $0.12.
How did Agios Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 137.7% from $8.7M a year earlier and eps declined 9.0% from $-1.55.
Where can I find Agios Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001439222-26-000071) and the 10-Q periodic report (0001439222-26-000073) directly on SEC EDGAR. The filing index links above go to sec.gov.